Balyasny Asset Management LLC C4 Therapeutics, Inc. Transaction History
Balyasny Asset Management LLC
- $63.6 Billion
- Q4 2024
A detailed history of Balyasny Asset Management LLC transactions in C4 Therapeutics, Inc. stock. As of the latest transaction made, Balyasny Asset Management LLC holds 42,533 shares of CCCC stock, worth $128,024. This represents 0.0% of its overall portfolio holdings.
Number of Shares
42,533
Previous 19,744
115.42%
Holding current value
$128,024
Previous $112,000
36.61%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding CCCC
# of Institutions
126Shares Held
63MCall Options Held
651KPut Options Held
115K-
Soleus Capital Management, L.P. Greenwich, CT6.98MShares$21 Million1.75% of portfolio
-
Lynx1 Capital Management LP San Juan, PR6.85MShares$20.6 Million9.58% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT6.07MShares$18.3 Million0.11% of portfolio
-
Ra Capital Management, L.P. Boston, MA4.88MShares$14.7 Million0.28% of portfolio
-
Black Rock Inc. New York, NY4.55MShares$13.7 Million0.0% of portfolio
About C4 Therapeutics, Inc.
- Ticker CCCC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,913,800
- Market Cap $147M
- Description
- C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...